Effects of the multi‐kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia

Recently, several targeted agents have been developed for specific subsets of patients with acute myeloid leukaemia (AML), including midostaurin, the first FDA‐approved FLT3 inhibitor for newly diagnosed patients with FLT3 mutations. However, in the initial Phase I/II clinical trials, some patients...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Cell Mol Med
Asıl Yazarlar: Weisberg, Ellen, Meng, Chengcheng, Case, Abigail E., Tiv, Hong L., Gokhale, Prafulla C., Buhrlage, Sara J., Yang, Jing, Liu, Xiaoxi, Wang, Jinhua, Gray, Nathanael, Adamia, Sophia, Sattler, Martin, Stone, Richard, Griffin, James D.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2020
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7077552/
https://ncbi.nlm.nih.gov/pubmed/31967735
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jcmm.14927
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller